Medicare Chief Clarifies TrumpRx as Limited Cash-Pay Drug Discount Platform

Chris Klomp, Medicare chief, described TrumpRx as a narrow, cash-pay tool rather than a broad drug pricing solution. This downplays President Trump’s claims of a transformative impact on prescription drug costs. Observers should watch how the platform’s limited scope affects actual drug price reductions for insured versus uninsured populations.